Abstract:Abstract Inflammatory bowel disease (IBD) is a complex, multifactorial set of diseases defined by chronic and relapsing inflammation of the gut. Changes in oxidative stress, inflammation, and metabolism are central to the disease process, linking mitochondrial health to IBD pathogenesis. Mitophagy is a quality-control mechanism that selectively removes dysfunctional mitochondria. Multiple mitophagy pathways co-exist in the intestine, including the canonical PINK1/PARKIN pathway and NIX. We have previously shown that NIX is increased in IBD, removing damaged mitochondria in the epithelium. Whether this translates to a physiologic increase in mitochondrial turnover remains unanswered. We hypothesized that mitophagy within the intestinal epithelium represents a key homeostatic response to inflammation. To study this hypothesis, we employed the use of a novel transgenic mouse expressing the pH-dependent fluorescent protein, mt-Keima, tethered to the mitochondria. Adult mt-Keima mice were subjected to chemically induced colitis (3% DSS) for 7 days to induce intestinal inflammation. In vivo mitophagic flux, measured via live-cell confocal microscopy, was increased nearly 4-fold (n=3, p<0.05) in DSS-treated animals compared to controls. Despite this consistent elevation, NIX expression varied in both human and mouse tissue, suggesting that other mitophagy pathways, like PARKIN, may be involved. Interestingly, activated PARKIN (pSer65-PARKIN) was higher in inflamed tissues of humans and mice as compared to controls, though variation was present. To determine the functional importance of PARKIN, Parkin-/- mice were subjected to a 7-day treatment of 2% DSS. These mice developed a more severe colitis, suggesting that Parkin-mediated mitophagy contributes to the mitochondrial damage response in IBD. These data collectively indicate that mitophagy is elevated in IBD, and both NIX and PARKIN likely work in parallel to respond to the elevated mitophagic demand. Interestingly, both NIX and pSer65-PARKIN expression are co-expressed in human control tissues, while both were generally expressed in inflamed biopsies, and at higher levels. We speculate that the mechanism of mitophagy may not necessarily be important, but that it is elevated in response to intestinal inflammation. To address this aim, we administered a known mitophagy inducer, urolithin A, to mice on a 7-day course of DSS. Urolithin A + DSS-treated mice had elevated NIX and pSer65-PARKIN expression compared to vehicle + DSS controls. This elevation correlated with decreased disease activity and improved O2 mitochondria respiration. We conclude that mitophagy is an imperative homeostatic response to remove superfluously damaged mitochondria in IBD and is amenable to therapeutic intervention. Elevating mitophagic flux might be a potential therapeutic option to help improve disease outcomes in IBD.

The conversion of redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in Janus family tyrosine kinase 3(-/-) and IL-2 receptor gamma(-/-) mice

Sequential conversion of the redox status of macrophages dictates the pathological progression of autoimmune diabetes

An altered REDOX environment, assisted by over-expression of fetal hemoglobins, protects from inflammatory colitis and reduces inflammatory cytokine expression

Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10.

P142 Genetic ablation of DNA methyltransferase 3A in myeloid cells impairs M1/M2 polarization and leads to pro-inflammatory macrophages

Myeloperoxidase Gene Deletion Causes Drastic Microbiome Shifts in Mice and Does Not Mitigate Dextran Sodium Sulphate-Induced Colitis

The Antioxidant Procyanidin Reduces Reactive Oxygen Species Signaling in Macrophages and Ameliorates Experimental Colitis in Mice

Enhanced Mucosal Defense and Reduced Tumor Burden in Mice with the Compromised Negative Regulator IRAK-M

A Novel Anti-inflammatory Phenotype Transformed by Repetitive Low-dose Lipopolysaccharide in Primary Peritoneal Tissue-resident Macrophages

MITOCHONDRIAL TURNOVER IS ELEVATED IN RESPONSE TO INTESTINAL INFLAMMATION AND IS AMENABLE TO THERAPUTIC TARGETING VIA UROLITHIN A

Macrophage LMO7 deficiency facilitates inflammatory injury via metabolic-epigenetic reprogramming

Integrative analysis of single-cell RNA-seq and gut microbiome metabarcoding data elucidates macrophage dysfunction in mice with DSS-induced ulcerative colitis

P061 The macrophage-specific role of PTPN23 in Acute and Chronic Colitis

Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency

Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease

The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease

Type I interferon signaling and peroxisomal dysfunction contribute to enhanced inflammatory cytokine production in Irgm1-deficient macrophages

Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during ulcerative colitis

P028 A pathogenic role of activated mucosal-associated invariant T cells in an animal model of Inflammatory Bowel Disease

The Crohn Disease-associated ATG16L1 T300A polymorphism regulates inflammatory responses by modulating TLR- and NLR-mediated signaling

The Protective Role of Transcription Factor Nrf2 in Murine Macrophage Activation Syndrome